Special Issue

Personalized Medicine in Dermatology

Message from the Guest Editors

The treatment landscape of dermatologic conditions has changed dramatically. Immune therapy and targeted treatments have revolutionized the field given their high efficacy and safety and are recommended as a first-line therapy in dermatologic disorders. The development of diagnostic and therapeutic guidelines has greatly reduced variation in clinical practice. Nevertheless, the extensive use of novel treatments has revealed considerable inter-individual variability regarding treatment response extent, promptness, and stability, as well as tolerance and adherence. Therefore, it has become obvious that a shift from a uniform, disease-centered treatment to a personalized one. centered on health maintenance, is needed to maximize efficacy and safety and reduce costs. We aim to gather and support both clinicians and researchers in sharing their experience with personalized treatment regimens. alongside the results of their innovative studies at the forefront of this particularly dynamic field. We warmly invite you to submit an original article or review on research areas such as inflammatory skin disease, bullous disorders, skin cancer, and genodermatoses, among others.

Guest Editors

Dr. Liliana Gabriela Popa

Dermatology Department, Carol Davila University of Medicine and Pharmacy, 030167 Bucharest, Romania

Prof. Dr. Calin Giurcaneanu

Dermatology Department, Carol Davila University of Medicine and Pharmacy, 030167 Bucharest, Romania

Deadline for manuscript submissions

25 January 2026



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/217226

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

